NCT03400163View on ClinicalTrials.gov

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 8, 2015

Primary Completion Date

January 18, 2017

Study Completion Date

June 19, 2017

Conditions
Non-Alcoholic Steatohepatitis
Interventions
DRUG

BMS-986036

BMS-986036 20 mg QD

DRUG

Placebo

Placebo QD

Trial Locations (2)

19107

Thomas Jefferson University Hospital, Philadelphia

78215

Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY